Form 4: Acrivon Therapeutics CLO Reports Tax Withholding Sale

Chief Legal Officer Mary Miller disposed of 558 shares of Acrivon Therapeutics to satisfy tax obligations upon RSU vesting.

Summary

• Mary Miller, Chief Legal Officer of Acrivon Therapeutics, Inc., reported the disposition of 558 shares of common stock.
• The transaction occurred on April 17, 2026, at a price of $1.78 per share.
• The shares were withheld by the company to satisfy mandatory tax withholding requirements related to the vesting of restricted stock units (RSUs).
• Following this transaction, the reporting person maintains beneficial ownership of 33,121 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the share reduction is purely for tax compliance and does not reflect a change in management sentiment regarding the company's prospects.

Positives

• The transaction was a routine administrative action related to tax obligations rather than a discretionary market sale.

Negatives

• The transaction represents a reduction in the direct equity holdings of a key executive.

Risks

• None identified; this is a standard regulatory disclosure for tax withholding.

Future Outlook

No forward-looking guidance or strategic outlook provided in this filing.

Industry Context

StockSavvy.ai notes that this filing is a routine administrative disclosure common in the biotechnology sector, where equity-based compensation is a standard component of executive remuneration packages.

Comparison to Industry Standards

• The transaction aligns with standard corporate governance practices for handling tax obligations upon the vesting of equity awards in publicly traded companies.

Stakeholder Impact

• Minimal impact on shareholders as the transaction is a standard tax-related withholding event.

Key Dates

Keywords

Acrivon Therapeutics, ACRV, Form 4, Insider Trading, Tax Withholding, Equity Vesting